Compare TRMB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRMB | ILMN |
|---|---|---|
| Founded | 1978 | 1998 |
| Country | United States | United States |
| Employees | 11500 | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 20.4B |
| IPO Year | 1996 | 2000 |
| Metric | TRMB | ILMN |
|---|---|---|
| Price | $68.79 | $122.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 17 |
| Target Price | $94.71 | ★ $124.24 |
| AVG Volume (30 Days) | 2.0M | ★ 2.0M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | 1.76 | ★ 5.45 |
| Revenue | $3,798,700,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $9.94 | $6.52 |
| Revenue Next Year | $8.22 | $5.49 |
| P/E Ratio | $39.78 | ★ $22.82 |
| Revenue Growth | ★ 3.33 | N/A |
| 52 Week Low | $52.91 | $68.70 |
| 52 Week High | $87.50 | $155.53 |
| Indicator | TRMB | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 42.17 |
| Support Level | $63.52 | $114.88 |
| Resistance Level | $68.92 | $135.68 |
| Average True Range (ATR) | 1.91 | 4.20 |
| MACD | 0.65 | 0.58 |
| Stochastic Oscillator | 63.64 | 36.19 |
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.